Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.24 and traded as low as $0.76. Atossa Therapeutics shares last traded at $0.82, with a volume of 572,873 shares traded.

Wall Street Analyst Weigh In

ATOS has been the topic of several research reports. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a research report on Thursday, January 30th. Finally, Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Price Performance

The business’s fifty day moving average price is $0.98 and its 200-day moving average price is $1.24. The stock has a market capitalization of $103.17 million, a PE ratio of -3.73 and a beta of 1.24.

Institutional Trading of Atossa Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATOS. SG Americas Securities LLC increased its holdings in shares of Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. Intech Investment Management LLC purchased a new position in shares of Atossa Therapeutics during the third quarter worth about $29,000. The Manufacturers Life Insurance Company bought a new position in shares of Atossa Therapeutics in the third quarter worth approximately $75,000. State Street Corp lifted its position in Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after purchasing an additional 69,180 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after buying an additional 24,951 shares in the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.